Fig. 6: Tuft cells and ILC2 are involved in human GC. | Nature Communications

Fig. 6: Tuft cells and ILC2 are involved in human GC.

From: A tuft cell - ILC2 signaling circuit provides therapeutic targets to inhibit gastric metaplasia and tumor development

Fig. 6

a, b Kaplan–Meier survival analysis for intestinal-type (IGC) and diffuse-type (DGC) GC patients segregated at the median level of gene expression for tuft cell (ChAT, IL25, POU2F3, TSLP, ALOX5, COX1, and AVIL) and ILC2 (GATA3, IL13, ICOS, KLRG1, CRTH2, IL5, and IL4) gene signatures. Data represents Kaplan–Meier plots depicting overall survival of GC patients from the GSE14210 (n = 145), GSE15459 (n-200), GSE22377 (n-43), GSE29272 (n = 268), GSE51105 (n = 94) and GSE62254 (n = 300) datasets. P value calculated with the Log-rank (Mantel-Cox) test. c Quantification of tuft cells and/or ILC2s in human intestinal-type GC tumor microarrays (Supplementary Fig. 8a) (n = 67 patients). d Tuft cell and ILC2 feed-forward circuit promotes gastric metaplasia and tumor development through IL25 and IL13 signaling. Proposed initiation of the circuit through Natural killer cell, macrophage/epithelial or T cell produced IL33, leading to increased secretion of IL13 by activated nILC2s. Created with BioRender.com.

Back to article page